NCT Number: NCT06546072
Deep Learning With MRI-based Multimodal-data Fusion Enhanced Postoperative Risk Stratification of Breast Cancer
Breast cancer poses a significant global health challenge, especially among women, with high rates of recurrence and distant spread despite early interventions. The timely identification of metastasis risk and accurate prediction of treatment strategies are critical for improving prognosis. However, the complex heterogeneity of breast tumors presents challenges in precise prognosis prediction. Therefore, the development of innovative methods for tumor segmentation and prognosis assessment is essential.
The research conducted is a multicenter study that enrolled 1,199 non-metastatic breast cancer patients from four independent centers. Our study leverages the advancements in artificial intelligence (AI) to address this challenge. This study is the first successful application of MRI-based multimodal prediction system to precisely identify the risk of postoperative recurrence in breast cancer patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Histologically confirmed stage I-III invasive BC
- Age ≥ 18 years
- The patient having undergone surgery
- The existence of MRI scans
Exclusion criteria
- Lacked pathological results
- Had other, simultaneous malignancies
- Had MR imaging issues were excluded
Treatment and study plan
Primary outcomes
-
DFS
Time frame: The time from surgery to tumor recurrence, including local and/or distant recurrence, disease progression, or death, assessed up to 100 months.
Disease-free survival
Sponsors and collaborators
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Other
Registry information
Important dates
- Study start
- 2011
- Primary completion
- 2019
- Study completion
- 2021
- First posted
- Aug 9, 2024
- Registry last updated
- Aug 9, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAfrican Cancer Genome: GMD
NCT05754658
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial Details24GUT540 : Meeting of Breast Cancer Patients and Pathologists
NCT07040514
Breast Cancer, Breast Diseases
Lebanon, New Hampshire, United States
View Trial DetailsNeoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
NCT06604858
Breast Cancer, Breast Diseases
A Coruña, Spain
View Trial Details